- Previous close
181.18 - Open
178.11 - Bid 175.34 x 100
- Ask 175.61 x 100
- Day's range
174.79 - 179.48 - 52-week range
174.79 - 268.30 - Volume
464,803 - Avg. Volume
1,104,370 - Market cap (intra-day)
25.57B - Beta (5Y monthly) -0.06
- PE ratio (TTM)
15.88 - EPS (TTM)
11.05 - Earnings date 30 Oct 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
260.77
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
www.biogen.com7,570
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent news: BIIB
View more
Performance overview: BIIB
Trailing total returns as of 31/10/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: BIIB
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: BIIB
View moreValuation measures
Market cap
26.39B
Enterprise value
31.34B
Trailing P/E
16.38
Forward P/E
10.43
PEG ratio (5-yr expected)
--
Price/sales (ttm)
2.75
Price/book (mrq)
1.61
Enterprise value/revenue
3.26
Enterprise value/EBITDA
12.52
Financial highlights
Profitability and income statement
Profit margin
16.81%
Return on assets (ttm)
5.05%
Return on equity (ttm)
10.47%
Revenue (ttm)
9.61B
Net income avi to common (ttm)
1.62B
Diluted EPS (ttm)
11.05
Balance sheet and cash flow
Total cash (mrq)
1.7B
Total debt/equity (mrq)
40.66%
Levered free cash flow (ttm)
--